A Clinical Study of TQH2929 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 21, 2023

Primary Completion Date

August 2, 2024

Study Completion Date

March 21, 2025

Conditions

Psoriasis

Interventions

DRUG

TQH2929 injection

TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.

DRUG

Placebo injection

Placebo comparator

Trial Locations (1)

Peking University First Hospital, Beijing

All Listed Sponsors

lead

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

INDUSTRY

NCT06156280 - A Clinical Study of TQH2929 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter